PALM2AKAP2

Across TCGA pan-cancer cohorts, PALM2AKAP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PALM2AKAP2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PALM2AKAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PALM2AKAP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where PALM2AKAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.683	0.973	.003	23	view →
PDAC	DFS	Quartile	All	0.819	0.630	.010	13	view →
HNSC	OS	Median	All	1.000	0.484	.038	12	view →
LSCC	DFS	Tertile	II,III,IV	0.835	1.000	.012	5	view →
CCRCC	DFS	Quartile	III,IV	1.000	0.570	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PALM2AKAP2–LUAD (DFS)

Open the LUAD breakdown →